Drug Search Results
More Filters [+]

AXT-914

Alternative Names: axt-914, axt914, axt 914
Latest Update: 2021-01-01
Latest Update Note: PubMed Publication

Product Description

a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women

Mechanisms of Action: CaSR Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AXT-914

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Osteoporosis|Acute Myeloid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CATF936A2201

P1

Completed

Osteoporosis|Acute Myeloid Leukemia

None

Recent News Events